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GABA, a major inhibitory neurotransmitter of the brain,
is also present at high concentration in pancreatic islets.
Current evidence suggests that within islets GABA is
secreted from f-cells and regulates the function of mantle
cells (a- and b-cells). In the nervous system GABA is
stored in, and secreted from, synaptic vesicles. The
mechanism of GABA secretion from f-cells remains to
be elucidated. Recently the existence of synaptic-like
microvesicles has been demonstrated in some peptide-
secreting endocrine cells. The function of these vesicles
is so far unknown. The proposed paracrine action of
GABA in pancreatic islets makes f-cells a useful model
system to explore the possibility that synaptic-like
microvesicles, like synaptic vesicles, are involved in the
storage and release of non-peptide neurotransmitters. We
report here the presence of synaptic-like microvesicles in
fl-cells and in f-cell lines. Some f-cells in culture were
found to extend neurite-like processes. When these were
present, synaptic-like microvesicles were particularly
concentrated in their distal portions. The GABA
synthesizing enzyme, glutamic acid decarboxylase
(GAD), was found to be localized around synaptic-like
microvesicles. This was similar to the localization
of GAD around synaptic vesicles in GABA-secreting
neurons. GABA immunoreactivity was found to be
concentrated in regions of f-cells which were enriched
in synaptic-like microvesicles. These findings suggest that
in f-cells synaptic-like microvesicles are storage organelies
for GABA and support the hypothesis that storage of
non-peptide signal molecules destined for secretion might
be a general feature of synaptic-like microvesicles of
endocrine cells.
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Introduction
GABA, the major inhibitory neurotransmitter of the brain,
is thought to play an important role as a signal molecule
also outside the nervous system (Erdo and Wolff, 1990).
In particular, evidence for a role of GABA as a paracrine
( Oxford University Press
signal molecule in pancreatic islets has been reported
(Rorsman et al., 1989; for a review see Okada, 1986).
Insulin-secreting fl-cells of the islets, like GABA-secreting
neurons (Oertel et al., 198 la,b; Nagai et al., 1984), contain
high levels of GABA (Briel et al., 1972; Okada et al.,
1976; Vincent et al., 1983), of the GABA-synthesizing
enzyme glutamic acid decarboxylase (GAD) and of GABA-
transaminase (Vincent et al., 1983). The function and
characteristics of the GABA system in the pancreas have
become the focus of considerable attention after the
demonstration that GAD is a dominant autoantigen in
insulin-dependent diabetes mellitus (Baekkeskov et al.,
1990).
GABA-A receptors have been found on a-cells and it has
been suggested that these receptors are involved in the
inhibition of glucagon release mediated by fl-cells (Rorsman
et al., 1989). A modulatory action of GABA on (-cells has
also been reported (Taniguchi et al., 1980). The direction
of blood flow in the islet is consistent with this hypothesis
because blood capillaries perfuse first the core of the islet,
composed of f-cells, and then the periphery (mantle) of the
islet, composed of a- and 6-cells (Bonner-Weir and Orci,
1982). However, the mechanism of GABA secretion from
f-cells is unknown. A previous immunocytochemical study
carried out with antibodies directed against GABA had
failed to reveal the presence of GABA in insulin-containing
granules. This finding suggested that GABA was secreted
via a non-vesicular mechanism (Garry et al., 1987).
It is currently accepted that in the nervous system GABA
is concentrated in, and secreted from, synaptic vesicles (Hell
et al., 1988), although a non-vesicular release of GABA at
certain specialized regions has been proposed (Schwartz
et al., 1987). Several intrinsic membrane proteins of synaptic
vesicles are also present in peptide-secreting endocrine
cells (Matthew et al., 1981; Buckley and Kelly, 1985;
Wiedenmann and Franke, 1985; Navone et al., 1986;
Baumert et al., 1989, 1990). Studies carried out on the
pituitary and the adrenal medulla, and on cell lines derived
from these tissues, have shown that in endocrine cells these
proteins are localized in the membranes of a population of
microvesicles distinct from peptide-containing secretory
granules (Navone et al., 1986; De Camilli and Navone,
1987; Wiedenmann et al., 1988; Johnston et al., 1989;
Baumert et al., 1989, 1990; Clift-O'Grady et al., 1990;
Cutler and Cramer, 1990; Schweitzer and Paddock, 1990;
for a review see De Camilli and Jahn, 1990). These vesicles,
referred to as 'synaptic-like microvesicles' (SLMVs) appear
to have at least some functional similarities in common with
synaptic vesicles of neurons, including the ability to undergo
exocytosis, endocytosis and recycling (Johnston et al., 1989;
Clift-O'Grady et al., 1990). The function of SLMVs remains
unknown. In view of their similarities with synaptic vesicles,
the possibility that SLMVs store and secrete
neurotransmitter-like molecules should be considered. Given
the proposed paracrine role of GABA in pancreatic islets,
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fl-cells appeared to be a useful model system to explore this
possibility.
The working hypothesis of this study was that secretion
of GABA from f-cells is mediated by SLMVs. If
this were the case, SLMVs of $-cells should share with
synaptic vesicles of GABA-secreting neurons specific
properties related to GABA uptake and storage. In this paper
evidence supporting this hypothesis is presented. We have
demonstrated the existence of SLMVs in :-cells and have
shown that, in analogy to the colocalization of GABA and
GAD with synaptic vesicles in GABA-secreting neurons,
GABA and GAD are colocalized with SLMVs in f-cells.
These results represent the first indication that, at least in
some endocrine cells, SLMVs might store neurotransmitter-
like molecules. This work has been presented previously in
abstract format (Reetz et al., 1990a,b).
Results
SLMVs are present in A-celIs
Expression of synaptic vesicle membrane proteins in pan-
creatic islets had been previously reported (Buckley and
Kelly, 1985; Navone et al., 1986; Baumert et al., 1989,
1990), but their precise subcellular localization had not been
investigated. An important preliminary step of our study was
to demonstrate that in f-cells these proteins are localized
on SLMVs, a population of microvesicles distinct from
secretory granules. To demonstrate this we used isolated
islets as well as cell lines derived from islet cells.
As markers for SLMVs we have used antibodies directed
against synaptophysin and p29, two major integral membrane
proteins of synaptic vesicles of neurons (Jahn et al.,
1985; Wiedenmann and Franke, 1985; Navone et al.,
1986; Baumert et al., 1990). As markers for secretory
granules we have used antibodies directed against insulin
and secretogranin I. Secretogranin I (also known as chromo-
granin B) is a peptide stored in secretory granules together
with peptide hormones in a variety of peptide-secreting
endocrine cells (Rosa et al., 1985b).
Figure la and b shows RINm5F cells (Gazdar et al., 1980;
Bhathena et al., 1982), a commonly used rat insulinoma cell
line, double-labeled for p29 and secretogranin I. Secreto-
granin I immunoreactivity was represented by puncta sparse
throughout the cytoplasm and particularly concentrated
at the enlarged tips of short thick cellular processes.
Electron microscopy immunocytochemistry (not shown),
demonstrated that each of these puncta corresponded to
individual secretory granules (Rosa et al., 1985a; and not
shown). p29 immunoreactivity had a distribution very
different from that of secretogranin I (Figure la) but virtually
identical to that of synaptophysin (Figure lc and d). Both
p29 and synaptophysin were present at low levels throughout
the cell but were particularly concentrated at a paranuclear
area, which included the Golgi complex as demonstrated by
double-labeling for synaptophysin and GIMPt, an intrinsic
membrane protein of the 'trans' region of the Golgi complex
(Yuan et al., 1987) (Figure le and f). The same results were
obtained by similar double-labeling experiments carried out
on another fl-cell line, fTC3 (Efrat et al., 1988) (Figure
lg and h). In both cell lines, synaptophysin was not
accumulated in the short thick processes rich in secretory
granules (Figure lb and not shown). However, some of the
flTC3 cells were found to extend relatively long, often
beaded, neurite-like processes. When this was the case,
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Fig. 1. Distribution of secretory granule proteins, of synaptic vesicle
proteins and of a marker antigen of the trans-Golgi (GIMPt) in
insulinoma cell lines. a-f: RINm5F cells double-labeled by
immunofluorescence for p29 and secretogranin I (secr I), for p29 and
synaptophysin (synapt.), and for synaptophysin and GIMPt; g and h:
,BTC3 cells double-labeled by synaptophysin and insulin. Puncta of
secretogranin I and insulin immunoreactivities, which correspond to
secretory granules, have a distribution very different from that of
synaptophysin and p29 immunoreactivities (compare a with b and g
with h). Both synaptophysin and p29 are primarily concentrated at a
paranuclear region which includes the Golgi complex (compare e with
f), where their distribution is very similar (compare c and d). The
calibration bar in the upper left corner is the equivalent of 10 um (a
and b), 7.6 am (c and d), 8.2 ytm (e and f) and 8.4 4m (g and h).
synaptophysin as well as secretory granule markers, were
concentrated in the distal portion of the processes (see Figure
Sc, e and g, Figure 8a and not shown).
The distribution of synaptophysin, p29 and secretogranin
I was studied by subcellular fractionation. A postnuclear
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Fig. 2. Separation of synaptic vesicle proteins from secretory granules
in a continuous sucrose density gradient. A 5000 g supernatant of a
total homogenate of RINm5F cells was loaded onto a sucrose gradient
ranging from 0.45 to 2 M sucrose. Fifteen fractions were collected
starting from the top and equal volumes of such fractions were
analyzed by SDS-PAGE and Western blotting with primary antibodies
directed against secretogranin I, synaptophysin and p29. Fractions 1-3
correspond to the 'load' of the gradient and contain soluble proteins.
Synaptophysin and p29 peak in a lighter portion (0.86-0.95 M
sucrose) of the gradient than do secretory granules (1.34- 1.47 M
sucrose) represented by secretogranin I immunoreactive bands. Some
endoproteolytic cleavage of secretogranin molecules is known to take
place in parallel with granule maturation (Rosa et al., 1985; Benedum
et al., 1987). Thus, lower mol. wt secretogranin immunoreactive
bands reflect the position in the gradient of mature granules.
supernatant of RINm5F cells was subjected to centrifugation
either on a Percoll gradient or on a continuous sucrose
density gradient. Fractions were collected and analyzed for
their content of synaptophysin, p29 and secretogranin I by
a Western blot procedure. Results obtained with the sucrose
gradient are shown in Figure 2. Synaptophysin and p29
immunoreactivities peaked near the top of the gradient
[density 0.86-0.95 M sucrose, similar to the density
previously described for neuronal synaptic vesicles (Navone
et al., 1989)]. Secretogranin I immunoreactivity was
accounted for by several bands as typically seen for proteins
of the chromogranin/secretogranin family which undergo
partial proteolytic processing during granule condensation
(Rosa et al., 1985b; Benedum et al., 1987). Mature secretory
granules, represented by the proteolytically processed
form of secretogranin I, peaked in the dense portion
(1.34-1.47 M sucrose) of the gradient and were well
separated from the peak of synaptophysin. Qualitatively
similar results were obtained when subcellular fractionation
was performed on a Percoll gradient (not shown). This
distribution confirms that synaptophysin and p29 are
localized on an organelle distinct from secretory granules.
The morphology of synaptophysin-positive organelles in
the endocrine pancreas was investigated by immunogold
electron microscopy. Figure 3 shows agarose-embedded
fragments of rat islets labeled for synaptophysin. Fragments
of f- and a-cells were identified by the typical morphological
features of their secretory granules (Williams and Porte,
1974). These have a characteristic dense core surrounded
by a clear halo in -cells and a homogeneous granular content
in a-cells (Williams and Porte, 1974). As demonstrated in
Figure 3a, b and c, mature insulin-containing granules were
d.1
Fig. 3. Gallery of electron micrographs showing the localization of
synaptophysin in fragments of rat pancreatic fl-cells as demonstrated by
an immunogold technique. a-C: gold labeling of pleiomorphic
microvesicles with a clear core. d: gold labeling of a cisternal element
in the region of the Golgi complex. Note lack of labeling of insulin-
containing secretory granules characterized by the typical unstained
halo around the granule core (a and c) which may have a crystal-like
shape (b). Calibration bars = 100 nm.
devoid of synaptophysin immunoreactivity. The predominant
pool of synaptophysin immunoreactivity was concentrated
on the membranes of pleiomorphic clear microvesicles and
tubules, with the same characteristics of SLMVs previously
identified in other endocrine cells. When fragments of the
Golgi complex were visible, synaptophysin immunoreactivity
was always present, but confined to its 'trans' side, where
it was localized both on vesicles and on cistemal and tubular
elements (Figure 3d). Synaptophysin was not detected at a
significant concentration on the plasma membrane. In
conclusion, the localization of synaptophysin in f-cells was
similar to that previously observed in other endocrine cells
(Navone et al., 1986; Baumert et al., 1990). Synaptophysin
was found to have a similar distribution also in a-cells (not
shown).
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Fig. 4. Selective expression of GAD in brain and in pancreatic f-cells
demonstrated by immunoprecipitation followed by Western blotting.
GAD was immunoprecipitated from detergent extracts (500 til each) of
cell lines and tissue using a sheep serum directed against GAD (Oertel
et al., 1981a). The immunoprecipitate was subjected to SDS-PAGE
and its GAD content analyzed by Western blotting using the rabbit
antibody directed against GAD described in Katarova et al. (1990). A
GAD doublet is visible in the extracts of brain, islets and 3TC3 cells,
but not in extracts of liver, RINm5F cells or csTCI1 cells. (No GAD
bands were detectable in the last three lanes irrespective of the
autoradiographic exposure time.)
GAD is concentrated around SLMVs ind7-cells and
around synaptic vesicles in neurons
The major pathway of GABA synthesis in neurons and in
fl-cells involves GAD (Wu et al., 1976; Oertel et al., 198 la),
an enzyme represented by two similar isoforms of mol. wt
-63 and 59 kd (Legay et al., 1987; Chang and Gottlieb,
1988; Erlander et al., 1990) which are expressed both in
the brain and in the pancreas (Baekkeskov et al., 1990).
GAD is not an integral membrane protein (Kobayashi et al.,
1987; Julien et al., 1990; Katarova et al., 1990; Wyborski
et al., 1990) but exhibits some hydrophobic properties which
night be consistent with membrane association (Baekkeskov
et al., 1990; Christie et al., 1990). Within GABA-secreting
neurons, GAD was found by immunofluorescence and by
inmunoperoxidase to be concentrated in regions containing
synaptic vesicle membranes, i.e. nerve terminals and the
region of the Golgi complex (Oertel et al., 198 lb; Mugnaini
and Oertel, 1985). If SLMVs of fl-cells and fl-cell lines had
a function similar to that of GABA-containing synaptic
vesicles, a colocalization of GAD with SLMV membranes
would be expected. This was investigated by light and
electron microscopy immunocytochemistry.
In preliminary experiments we determined that the f-cell
line flTC3 expresses GAD. This was demonstrated both
by immunoprecipitation and by immunofluorescence
experiments (see below and not shown). For the former
experiments cell extracts were immunoprecipitated with
antibodies directed against GAD (or control antibodies) and
the GAD content in the immunoprecipitates was determined
by Wester blotting with a different anti-GAD antibody. A
doublet of immunoreactive bands with mol. wts 63 and
59 kd, corresponding to the two isoforms of GAD, was
detected in brain, pancreatic islets and in fTC3 cells (Figure
4). As expected, GAD was not detected in a liver extract
or in aiTC1 cells, a glucagonoma cell line (Powers et al.,
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1990) (Figure 4). GAD was also not detected in RINm5F
cells (Figure 4). While they are often used as a model for
f-cells, recent evidence suggests that RINm5F cells exhibit
some characteristics typical of at-cells (Halban et al., 1988).
It is noteworthy that RINm5F cells were previously found
to be negative for the 64 kd antigen of insulin-dependent
diabetes (Colman et al., 1987), now known to be identical
to GAD (Baekkeskov et al., 1990).
The distribution of GAD in the OTC3 cell line was
investigated by immunofluorescence and compared with the
distribution of a marker protein of SLMVs, synaptophysin,
GAD immunoreactivity was detected only in a subpopulation
of cells which included all the cells with neurite-like
processes (Figure 5a-h, see also Figure 8). Within GAD-
positive cells, the distribution of GAD and of synaptophysin
was very similar (Figure 5a-h). GAD, like synaptophysin,
was concentrated in the Golgi complex area and in the distal
portions of neurite-like extensions. The virtually identical
distribution of the two antigens was particularly impressive
in the tips of the processes as shown at higher magnifica-
tion in Figure Se-h. The colocalization of GAD with
synaptophysin visible in the processes was similar to the
colocalization of the same two antigens in axons and growth
cones of primary neuronal cultures double-labeled by the
same procedure (Figure Si -1).
The subcellular localization ofGAD in pancreatic fl-cells
was further investigated using electron microscopy colloidal
gold immunocytochemistry on agarose-embedded tissue
fragments of pancreatic islets. Gold particles were found
to be concentrated in proximity to the membranes of
pleiomorphic microvesicles and of tubular and cisternal
elements (Figure 6). The latter were, in general, in close
proximity to the Golgi complex. This localization of GAD
was similar to the localization of synaptophysin in the same
cells. However, in the case of GAD, a low level of GAD
immunolabeling was observed throughout the cytoplasm.
When the same immunocytochemical technique was
applied to cerebellar tissue fragments, a low level of
immunolabeling was observed throughout the cytoplasm of
GABA-secreting neurons. Very intense immunolabeling was
observed in nerve terminals. Within nerve terminals gold
labeling was primarily associated with synaptic vesicles,
while other nerve terminal membranes were virtually
unlabeled (Figure 7).
The interaction of GAD with brain synaptic vesicles and
with SLMVs of f-cells was investigated by subcellular
fractionation. However, GAD could not be recovered on
synaptic vesicles or on SLMVs purified by immuno-isolation
(Burger et al., 1989), and GAD did not copurify with
synaptic vesicles or with any other membranous organelle
in sucrose density gradients or in glycerol velocity gradients
(unpublished observations). These findings suggested that
the interaction between GAD and vesicles is either indirect
or highly sensitive to homogenization conditions.
GABA is colocalized with SLMVs in ,B-cells
Antibodies specific for GABA have proved to be a useful
tool to identify sites where GABA is present at high
concentration by immunocytochemistry. Immunostaining of
brain sections with antibodies directed against GABA results
in the selective labeling of GABA-ergic nerve terminals, i.e.
of nerve terminals containing synaptic vesicles specialized
for the storage of GABA (Storm-Mathisen et al., 1983). If
GABA storage and secretion
Fig. 5. Colocalization of synaptophysin (synapt.) and GAD in ,BTC3 cells and in primary cultures of hippocampal neurons as demonstrated by
double-immunofluorescence. a-h: ,BTC3 cells. The two antigens colocalize both in the Golgi complex area (a-d) as well as in neurite-like processes
(c and d). The tips of two such processes are shown at higher magnification (e and f, g and h). i-I: neurons. Colocalization of the two antigens in
axonal growth cones (i and j) and in segments of isolated axons (k and 1) is shown. The calibration bar in the upper left corner is the equivalent of
8.7 ltm (a-d), 7.0 zm (e-h) and 8.3 Asm (i-I).
SLMVs of fl-cells contain GABA in a concentrated form,
then GABA immunoreactivity should colocalize with
SLMVs. When ,BTC3 cells were labeled with antibodies
directed against GABA, immunoreactivity was found to be
particularly high in cells with neurite-like processes, and in
these cells it was preferentially localized in these processes
(Figure 8b and d). Double-staining of these cells for GABA
and for synaptophysin resulted in a very similar immunostain
within the processes (Figure 8a and b), while a detectable
accumulation of GABA immunoreactivity was not seen in
the region of the Golgi complex. Double-staining of the same
cells for GABA and for GAD demonstrated that the cells
containing high levels of GABA were the same as those
expressing high levels of GAD (Figure 8c and d). GABA
immunoreactivity was not detected in the ctTC1 cells, the
GAD-negative a-cell line (see above).
Discussion
Over the last several years growing evidence for a paracrine
role of GABA in pancreatic islets has accumulated. GABA
is thought to be released from $-cells and to act on a- and
possibly b-cells, but until now its mechanism of secretion
was unknown (Taniguchi et al., 1980; Robbins et al., 1981;
Cavaginini et al., 1982; Passariello et al., 1982; Rorsman
et al., 1989). We report here results supporting the
hypothesis that GABA might be secreted from f-cells via
SLMVs. These findings provide an initial insight concerning
the possible function of SLMVs in endocrine cells.
SLMVs are organelles of a vesicular pathway distinct from
the typical 'regulated secretory pathway' of endocrine cells
and defined by the presence in their membranes of several
of the major membrane proteins of synaptic vesicles (Navone
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Fig. 7. Electron micrograph showing the localization of GAD in a
brain nerve terminal demonstrated by immunogold. Gold particles are
concentrated around synaptic vesicles. The plasma membrane and other
membranes of the ending are unlabeled. Calibration bar = 100 nm.
a C
Fig. 6. Gallery of electron micrographs showing the localization of
GAD in $-cells as demonstrated by an immunogold technique.
Fragments of rat islets were agarose embedded and immunolabeled as
described (De Camilli et al., 1983; Mignery et al., 1989). Portions of
fl-cells are shown in panels a-c. Calibration bars = 100 nm.
et al., 1986; De Camilli and Navone, 1987; Wiedenmann
et al., 1988; Baumert et al., 1989, 1990; Clift-O'Grady
et al., 1990; Cutler and Cramer, 1990; Fischer von Mollard
et al., 1990; Schweitzer and Paddock, 1990). Like synaptic
vesicles they undergo exocytosis, endocytosis and recycling
(Navone et al., 1986; Johnston et al., 1989; Clift-O'Grady
et al., 1990). SLMVs were previously described in
chromaffin and pituitary cells and are shown by this study
to be present in cells of the endocrine pancreas.
The similarities between SLMVs of endocrine cells and
neuronal synaptic vesicles strongly suggest that the function
of the two organelles is somehow related. The function
of synaptic vesicles is to store and secrete non-peptide
neurotransmitter molecules (Hokfelt et al., 1984). In this
study we have addressed the possibility that this function
might be shared by SLMVs. To do so, we have taken
advantage of the known property of pancreatic f-cells to
secrete the neurotransmitter GABA and we have used f-cells
as a model endocrine cell.
Our present results show that synaptic vesicles of GABA-
secreting neurons and SLMVs of f-cells share, in addition
to properties common to all synaptic vesicles and SLMVs,
an important property relevant to GABA uptake and storage,
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namely the concentration of the GABA-synthesizing enzyme
GAD at their cytoplasmic surface. An association of GAD
with synaptic vesicles had been inferred previously by
electron microscopy immunoperoxidase studies (McLaughlin
et al., 1975), but in those studies the peroxidase reaction
product was found on all organelles of nerve terminals.
Non-specific labeling of all membranous compartments
adjacent to antigenic sites is a known limitation of immuno-
peroxidase techniques (De Camilli et al., 1983). We have
now provided strong evidence for a specific localization of
GAD around synaptic vesicles using an electron microscopy
immunogold procedure on brain tissue and immunofluor-
escence on primary neuronal cultures. Likewise, we have
shown a localization of GAD around SLMVs of $-cells by
electron microscopy immunogold labeling of pancreatic islets
and by immunofluorescence on $-cell lines.
The distribution ofGAD both in neurons and in endocrine
cells suggests a direct or indirect interaction of at least a
significant pool of the protein with vesicle membranes.
However, a direct association of GAD with synaptic vesicles
or with SLMVs could not be demonstrated by subcellular
fractionation studies. Although a pool of GAD, variable
depending upon the homogenization conditions, was found
to be sedimentable by high speed centrifugation (100 000 g
for 1 h). However, this pool could not be recovered on
synaptic vesicles or on SLMVs by either immuno-isolation
experiments or by sucrose density gradient centrifugation.
It appeared to represent insoluble GAD not bound to
membranes (unpublished observations). These findings
indicate either that the interaction ofGAD with membranes
is indirect or that our conditions of homogenization abolish
the interaction. The primary sequence of GAD does not
include typical transmembrane regions (Kobayashi et al.,
1987; Katarova et al., 1989; Julien et al., 1990; Wyborski
et al., 1990). However, a significant pool ofGAD partitions
in the detergent phase after Triton X-1 14 extraction
(Baekkeskov et al., 1990), suggesting the existence of
post-translational hydrophobic modifications of the molecule.
These modifications may mediate a membrane attachment
labile to homogenization conditions. The nature of the
association between GAD and vesicle membranes needs to
be further investigated. This issue deserves special interest
GABA storage and secretion
Fig. 8. Colocalization of GABA with synaptophysin (synapt.) and with GAD in ,BTC3 cells demonstrated by double-immunofluorescence. Note that
GABA is present at high concentrations only in cells that express high levels of GAD (compare c with d) and that these cells include all the ones
with neurite-like processes. GABA is particularly concentrated in the processes where it is colocalized both with synaptophysin and with GAD.
Calibration bar = 10 zm.
because it may provide some clues concerning the properties
of GAD as a major autoantigen in Stiff-Mann syndrome
and insulin-dependent diabetes mellitus (Solimena et al.,
1990; Baekkeskov et al., 1990).
We have also demonstrated here that GABA is concen-
trated in regions of $-cells which are enriched in SLMVs, as
would be expected if SLMVs contain GABA. A similar
colocalization of GABA with synaptic vesicles can be
observed in neurons (our study and Storm-Mathisen et al.,
1983).
Morphologically, as assessed by electron microscopy
immunocytochemistry, SLMVs are small, translucent,
pleiomorphic vesicles and tubules (Navone et al., 1986;
Baumert et al., 1990; this study). In endocrine cells in situ,
and in cultured endocrine cells devoid of neurite-like
processes, SLMVs are scattered throughout the cytoplasm
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but are primarily concentrated in the region of the Golgi
complex. In these regions they are localized at the trans-side
and occupy a space which includes the trans-Golgi network
(Navone et al., 1986; Baumert et al., 1990; Schweitzer and
Paddock, 1990; this study). The localization of SLMVs in
the Golgi complex area is thought to reflect the transit of
recycling SLMV membranes, because after incubation of
PC 12 cells in the presence of extracellular tracers, tracer-
positive SLMVs rapidly appear in this region (Johnston
et al., 1989; De Camilli and Jahn, 1990). If SLMVs are
indeed involved in a regulated release of signal molecules,
lack of a significant accumulation of SLMVs under the
plasmalemma suggests that regulation of SLMV exocytosis
differs from regulation of synaptic vesicle exocytosis. This
is not unexpected given the different characteristics of
endocrine and synaptic signalling. A large reserve pool of
vesicles in the proximity of release sites might be needed
in nerve terminals but not in endocrine cells.
In cultured endocrine cells which extend neurite-like
processes, SLMVs are concentrated in the distal portions
of the processes. This property, which was shown previously
for other endocrine cells (Tooze et al., 1989; Schweitzer
and Paddock, 1990), and is shown here for f-cells, further
emphasizes the relationship between SLMVs and synaptic
vesicles, because synaptic vesicles accumulate in the distal
axonal arbour. It has been shown that axonal differentiation
of a neuronal process occurs only after it has reached a
critical length (Goslin and Banker, 1989). Thus, it was of
interest that in f-cells, SLMVs were concentrated only
in the distal portions of processes with neurite-like
characteristics (long, often beaded processes) but not in short,
thick cellular extensions. In contrast, both types of processes
were enriched in secretory granules, as typically seen in pro-
cesses of endocrine cells (Tooze and Burke, 1987).
Accumulation of SLMVs in the distal portions of neurite-
like processes might reflect a local exo-endocytotic
recycling similar to the well known local exo -endocytotic
recycling of synaptic vesicles in neuronal axons.
The colocalization of GABA with SLMVs was particularly
impressive in the neurite-like processes where both GABA
and SLMVs were present at the highest concentrations. In
contrast, GABA was not colocalized with synaptic vesicle
markers in the region of the Golgi complex. This observation
may suggest that the property to take up GABA operates
primarily in SLMVs located at the cell periphery, possibly
SLMVs ready for exocytosis.
Concluding remarks
The existence of a variety of important biochemical and
functional similarities between peptide-secreting endocrine
cells and neurons is well known (Grazl and Langley, 1990).
These similarities had led in the past to the speculation that
most peptide-secreting endocrine cells and neurons have a
common embryological origin from the neural crest (Pearse,
1977). It is now clear that at least some endocrine cells,
including cells of pancreatic islets, are of endodermal origin
(Le Douarin, 1988). Yet, a close relationship between
pancreatic endocrine cells and neurons has been shown
(Polak et al., 1984; Navone et al., 1986; Eisenbarth et al.,
1987; Teitelman and Lee, 1987; Teitelman et al., 1987a,b;
Alpert et al., 1988; Baumert et al., 1989, 1990). The
identification of SLMVs in endocrine cells is a novel
important element of similarity between endocrine cells and
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neurons. We have previously hypothesized that synaptic
vesicles may represent a neuron-specific adaptation of
SLMVs (De Camilli and Navone, 1987; De Camilli and
Jahn, 1990). Our present results, suggesting a role of SLMVs
of f-cells in the storage and secretion of the neurotransmitter
GABA, strengthen this hypothesis. Studies aimed at pro-
viding a direct biochemical demonstration of the presence
of GABA and GABA-uptake mechanisms in SLMVs of$-cells are currently under way in our laboratory.
It will be of interest to determine whether SLMVs of
all endocrine cells contain non-peptide substances with
paracrine/endocrine functions. Different neuronal sub-
populations differ in their neurotransmitter phenotype.
Expression of the GABA system only in a subpopulation of
endocrine cells, and, more specifically, of a subpopulation
of cells of the endocrine pancreas, is consistent with the
possibility that a similar heterogeneity applies to endocrine
cells. The property to co-secrete peptide and non-peptide
signal molecules might be a general characteristic of neurons
and endocrine cells.
Materials and methods
Animals
Sprague -Dawley rats weighing - 150 g were purchased from Charles
River.
Antibodies
The following antibodies were obtained as generous gifts: affinity-purified
polyclonal antibodies directed against p29 (Baumert et al., 1990) and
monoclonal and affinity-purified polyclonal antibodies directed against
synaptophysin (Navone et al., 1986) from R.Jahn (Munich); polyclonal and
monoclonal antibodies directed against secretogranin I (Rosa et al., 1985b)
from W.Huttner (Heidelberg); a sheep serum directed against GAD (Oertel
et al., 1981a) from E.Mugnaini (Storrs, CT); a monoclonal antibody against
GAD (Chang and Gottlieb, 1988) from D.Gottlieb (St Louis, MO); a rabbit
serum directed against GAD (Katarova et al., 1989) from Z.Katarova and
R.J.Greenspan (Nutley, NJ); a rabbit antibody directed against GABA
(Wenthold etal., 1986) from R.J.Wenthold (Washington, DC); a monoclonal
antibody directed against GIMPt (Yuan et al., 1987) from Dr C.A.
Suarez-Quian (Washington, DC). Human antibodies directed against GAD
were obtained from the cerebrospinal fluid of a patient affected by
Stiff-Mann syndrome (Solimena et al., 1990). The following immunological
reagents were purchased: anti-insulin (chicken) and anti-chicken IgG (goat)
sera (Sera Lab, Westbury, NY); anti-rabbit IgG (goat), anti-sheep IgG (goat)
and normal (goat) sera (Cappel, Westchester, PA); anti-mouse IgG (goat)
(Sigma, St Louis, MO). Protein A-colloidal gold conjugates (4-8 nm)
were prepared as described in Slot and Geuze (1983). 5 nM gold-conjugated
anti-human IgGs (goat) were from E-Y Laboratories (San Mateo, CA).
Pancreatic cell lines
RINm5F cells (Gazdar et al., 1980; Bhathena et al., 1982) were a kind
gift from L.Vallar (Milano) and K.Wollheim (Geneve). They were grown
in RPMI 1640 medium supplemented with 10% fetal calf serum as described
(Bhathena etal., 1982). ,3TC3 (Efrat et al., 1988) and aTC1 cells (Powers
etal., 1990) were a kind gift from D.Hanahan (San Francisco, CA). These
cell lines were grown in Click medium (Irvine Scientific, Santa Ana, CA)
supplemented with 5 % fetal calf serum.
Islet isolation
Islets were isolated from rats as described by Bowen et al. (1980).
Neuronal cultures
Primary neuronal cultures were prepared from the hippocampi of 18-day-old
fetal rats as described by Banker and Cowan (1977) and Bartlett and Banker
(1984). Briefly, hippocampi were dissociated by treatment with trypsin (0.1%
for 15 min at 37°C), followed by trituration with a fire-polished Pasteur
pipette. Dissociated cells were plated on poly-A-lysine-treated glass coverslips
in MEM supplemented with 2 mM glutamine, 1% HL1 (Ventrex, Portland,
ME), 10% horse serum, 5% fetal calf serum at densities ranging from 16 000
to 50 000 cells/cm2. The following day, coverslips were transferred (upside
down) to dishes containing a monolayer of cortical glial cells, so that they
GABA storage and secretion
were suspended over the glia but not in contact with them (Bartlett and
Banker, 1984). Cells were maintained in MEM without sera, supplemented
with 1% HL1, 2 mM glutamine and 1 mg/ml BSA.
Immunofluorescence
Pancreatic cell lines grown on poly-ornithine (100 itg/ml)-coated glass
coverslips (50-70% confluency) and primary neurons after 5 days in vitro
were used. Cells were fixed for 1 h at 4°C with 4% paraformaldehyde
(freshly prepared from paraformaldehyde) in 0.12 M Na-phosphate buffer,
pH 7.4. When cells were to be stained with antibodies directed against
GABA, glutaraldehyde (0.1% final concentration) was added to the fixative
and immunostaining was preceded by a 5 min incubation in 1 % sodium
borohydride to quench glutaraldehyde-induced autofluorescence.
The cells were rinsed with phosphate buffer and then permeabilized for
30 min in goat serum dilution buffer (GSDB: 17% goat serum, 0.3% Triton
X-100, 0.45 M NaCI, 20 mM Na-phosphate buffer, pH 7.4). They were
then double-stained by immunofluorescence using standard procedures
involving secondary antibodies coupled to fluorescein and rhodamine (De
Camilli et al., 1983; Johnston et al., 1989). All antibody incubations were
performed in GDSB for 2 h at room temperature. Coverslips were mounted
in 70% glycerol, 10 mg/ml phenylenediamine in PBS, observed in a Zeiss
Axiophot microscope and photographed with T-Max 100 (Kodak).
Equilibrium sucrose density gradients
RINmSF cells were grown in ten 100 mm tissue culture dishes to - 70%
confluency (-5 x 106 cells/dish). Cells were detached from the dishes
by a 20 min incubation in PBS containing 10 mM EDTA at 370C, pelleted
by centrifugation, resuspended in 500 11 of homogenization buffer [250 mM
sucrose, 1 mM MgCl2, 0.005% DNase (Sigma, St Louis, MO), 4 mM
HEPES, pH 7.4, and the following protease inhibitors: 0.4 mM PMSF
(Boehringer-Mannheim, Indianapolis, IN), 10 mM benzamidine (Sigma,
St Louis, MO) and 4 Ag/ml each of pepstatin A, leupeptin, antipain and
Aprotinin (Sigma)] and passed four to six times through a ball-bearing
homogenizer (clearance: 0.0028 inches; Berni-Tech, Saratoga, CA). The
homogenate was centrifuged (5000 g for 10 min at 4°C) and the superna-
tant [post nuclear supernatant (PNS)] recovered. EDTA was added to the
PNS to a final concentration of 1.5 mM. The PNS was then loaded onto
the top of a continuous sucrose density gradient (0.45-2 M sucrose, 1.5 mM
EDTA, 4 mM HEPES, pH 7.4) and centrifuged at 30 000 r.p.m. for 18 h
at 4°C in a SW41 rotor (Beckman, Fullerton, CA). Fractions (750 y1) were
collected from the top of the gradient. The sucrose molarity of each fraction
was determined by measuring its refractive index. Fractions were then
analyzed by SDS-PAGE and Western blotting.
Immunoprecipitation assays
Preparation of cell and tissue extracts. Cells grown in 100 mm dishes were
harvested and pelleted as described for sucrose density gradients. The cell
pellet was resuspended in (200 ll/dish) ice-cold buffer A (150 mM NaCI,
10 mM HEPES, pH 7.4, protease inhibitors as described above) containing
2% Triton X-100 and incubated on ice for 2 h. Insoluble material was
removed by centrifugation (16 000 g for 30 min, 4C). The remaining
supernatant was stored at -20°C and used for immunoprecipitations. The
protein concentration of the extracts varied between 1.0 and 1.5 mg/mi for
the different cell lines. Rat brain and liver were homogenized in 10 vol
(w/v) of buffer A using a polytron homogenizer (30 s on ice). The
homogenate was then spun at 100 000 g for 60 min at 4°C and the pellet
was resuspended in 40 mi of ice cold homogenization buffer containing either
Triton X-100 (2% w/v) or Triton X-1 14 (2% w/v) and incubated on ice
for 2 h. Insoluble material was removed as described for cells. The Triton
X-1 14 supernatant was further processed as described (Bordier, 1981). Both
Triton X-100 and Triton X- 1 14 were diluted 1: 1 in homogenization buffer
before use; the final protein concentration was 0.5 mg/ml (Triton X-1 14
brain extract), 1.2 mg/ml (Triton X-100 brain extract) and 0.625 mg/ml
(Triton X-1 14 liver extract). Approximately 500 freshly dissociated rat islets
were pelleted and resuspended in 500 yI buffer A with 2% Triton X-100.
They were further processed as described for cells, above.
Immunoprecipitation. Preclearing of detergent extracts was performed as
follows. Control human serum (25 ttl) was added to 0.5 ml of each extract.
After 1 h incubation, 100 ul of 50% protein A-Sepharose (Pharmacia,
Uppsala, Sweden) was added to each sample, the samples were incubated
for an additional hour and centrifuged at 750 g for 1 min. The resulting
supernatants were incubated for an additional hour with 100 ul of 50%
protein A-Sepharose and centrifuged as described above.
For immunoprecipitation, the following additions were made in sequential
order to precleared extracts incubated with rotation: 1.5 /1l of sheep serum
directed against GAD or preimmune sheep serum (Oertel et al., 1981a)
(16 h), 20 izl of rabbit IgGs directed against sheep IgGs (1.5 h), 125 ud of
50% protein A-Sepharose (1.5 h). The samples were then centrifuged
(750 g for 1 min) and the resulting protein A-Sepharose pellets were washed
three times in 150 mM NaCI, 10 mM HEPES, pH 7.4. All preclearing
and immunoprecipitation steps were carried out at 4°C. The final washed
pellet was solubilized in 75 yl of gel sample buffer (Laemmli et al., 1970)
(0.0625 M Tris-Cl, pH 6.8, 2% SDS, 10% glycerol, 30 mM DTT,
bromophenol blue), heated at 100°C for 3 min, and centrifuged at 16 000 g
for 10 min. The supernatants were removed and stored at -20'C.
Immunoprecipitates were analyzed by SDS -PAGE and Western blotting.
Miscellaneous analytical procedures
Proteins were measured by the BCA assay (Pierce). SDS-PAGE was
performed according to Laemmli et al. (1970). Western blotting was
performed as described by Towbin et al. (1979) using a [1251]protein A
(Amersham, Arlington Heights, IL) radioimmunolabeling procedure.
Electron microscopy
Electron microscopy immunocytochemistry was performed essentially as
described by De Camilli et al. (1983) and modified by Mignery et al. (1989).
Briefly, fresh dissociated rat islets or rat brains were mildly homogenized
in 0.25 M sucrose, 25 mM KCI, 10 mM Na-phosphate buffer, pH 7.4,
by passing them a few times through a loosely fitting glass-Teflon
homogenizer. The resulting tissue fragments were fixed, embedded in
agarose, labeled by an immunogold procedure and finally embedded in plastic
and processed for electron microscopy observations as described. Affinity-
purified antibodies directed against synaptophysin followed by protein
A -gold were used for the anti-synaptophysin immunostain. A human CSF
containing autoantibodies specifically directed against GAD (Solimena et
al., 1980) followed by gold-conjugated goat anti-human IgGs was used for
the anti-GAD immunostain. The specificity of these antibodies was previously
reported [case no. 161 of Solimena et al. (1990) identical to case no. 2
of Schwartzmann et al. (1991)].
Acknowledgements
We thank Dr D.Hanahan for making pancreatic endocrine cell lines available
to us, Drs C.Janeway and P.Reich for suggestions on the culture of these
cells and for discussion, and Dr R.Jahn for critically reading the manuscript.
We also thank Drs R.Jahn, W.Huttner, E.Mugnaini, Z.Katarova, R.J.
Greenspan, C.A.Suarez-Quian and R.J.Wenthold for generous gifts of
antibodies, Dr L.Vallar for a gift of RlNmSF cells, J.Morgan for help and
advice in the islet isolation procedure, H.Stukenbrok and R.Aparisi for
assistance in ultramicrotomy and M.Guidi for help in the preparation of
the illustrations. This work was supported by grants from NIH (Al 30248-01
and DK 43078-01), NIMH (MH 45191-OlAl), the Klingenstein Founda-
tion and the Diabetes Research and Education Foundation (P.DeC), by
postdoctoral fellowships from MDA (M.S.) and EMBO (M.M.) and by
the 'Dottorato di Ricerca' University of Milano (F.F.). M.M. was the reci-
pient of an IBRO McArthur travel award.
References
Alpert,S., Hanahan,D. and Teitelman,G. (1988) Cell, 53, 295-308.
Baekkeskov,S., Aanstoot,H.-J., Christgau,S., Reetz,A., Solimena,M.,
Cascalho,M., Folli,F., Richter-Olesen,H. and De Camilli,P. (1990)
Nature, 347, 151-156.
Banker,G.A. and Cowan,W.M. (1977) Brain Res., 126, 397-425.
Bartlett,W.P. and Banker,G.A. (1984) J. Neurosci., 4, 1944-1953.
Baumert,M., Maycox,P.R., Navone,F., De Camilli,P. and Jahn,R. (1989)
EMBO J., 8, 379-384.
Baumert,M., Takei,K., Hartinger,J., Burger,P.M., Fischer von Mollard,G.,
Maycox,P.R., De Camilli,P. and Jahn,R. (1990) J. Cell Biol., 110,
1285-1294.
Benedum,U.M., Lamouroux,A., Konecki,D.S., Rosa,P., Hille,A.,
Baeuerle,P.A., Frank,R., Lottspeich,F., Mallet,J. and Huttner,W.B.
(1987) EMBO J., 6, 1203-1211.
Bhathena,S.J., Oie,H.K., Gazdar,A.F., Voyles,N.R., Wilkins,S.D. and
Recant,L. (1982) Diabetes, 31, 521-531.
Bonner-Weir,S. and Orci,L. (1982) Diabetes, 31, 883-889.
Bordier,C. (1981) J. Biol. Chem., 256, 1604-1607.
Bowen,K.M., Andrus,L. and Lafferty,K.J. (1980) Diabetes, 29 (suppl. 1),
98-104.
Briel,G., Gylfe,E., Hellman,B. and Neuhoff,V. (1972) Acta Physiol., 84,
247-253.
Buckley,K. and Kelly,R.B. (1985) J. Cell Biol., 100, 1284-1294.
Burger,P.M., Mehl,E., Cameron,P.L., Maycox,P.R., Baumert,M.,
1283
A.Reetz et al.
Lottspeich,F., De Camilli,P. and Jahn,R. (1989) Neuron, 3, 715-720.
Cavagnini,F., Pinto,M., Dubini,A., Invitti,C., Cappelletti,G. and Polli,E.E.
(1982) Metabolism, 31, 73-77.
Chang,Y.-C. and Gottlieb,D.I. (1988) J. Neurosci., 8, 2123-2130.
Christie,M.R., Pipeleers,D.G., Lernmark,A. and Baekkeskov,S. (1990)
J. Biol. Chem., 265, 376-381.
Clift-O'Grady,L., Linstedt,A.D., Lowe,A.W., Grote,E. and Kelly,R.B.
(1990) J. Cell Biol., 110, 1693-1703.
Colman,P.G., Campbell,I.L., Kai,T.W.H. and Harrison,L.C. (1987)
Diabetes, 36, 1432-1440.
Cutler,D.F. and Cramer,L.P. (1990) J. Cell Biol., 110, 721-730.
De Camilli,P. and Jahn,R. (1990) Annu. Rev. Physiol., 52, 625-645.
De Camilli,P. and Navone,F. (1987) Ann. N. Y Acad. Sci., 493, 461-479.
De Camilli,P., Harris,S.M., Huttner,W.B. and Greengard,P. (1983) J. Cell
Biol., 96, 1355-1373.
Efrat,S., Linde,S., Kofod,H., Spector,D., Delannoy,M., Grant,S.,
Hanahan,D. and Baekkeskov,S. (1988) Proc. Natl Acad. Sci. USA, 85,
9037-9041.
Eisenbarth,G.S., Shimuzu,K., Bowring,M.A. and Wells,S. (1987) Proc.
Natl Acad. Sci. USA, 79, 5066-5070.
Erdo,L.F. and Wolff,J.R. (1990) J. Neurochem., 54, 363-372.
Erlander,M.G., Tilakaratne,N.J.K., Feldblum,S., Patel,N. and Tobin,A.J.
(1990) Neurosci. Soc. Abstr., 16, 960.
Fischer von Mollard,G., Mignery,G.A., Baumert,M., Perin,M.S.,
Hanson,T.J., Burger,P.M., Jahn,R. and Sudhof,T.C. (1990) Proc. Natl
Acad. Sci. USA, 87, 1988-1992.
Garry,D.J., Sorenson,R.L. and Coutler,H.D. (1987) Diabetologia, 30,
115-119.
Gazdar,A.F., Chick,W.L., Oie,H.K., Sims,H.L., King,D.L., Weir,G.C.
and Lauris,V. (1980) Proc. Natl Acad. Sci. USA, 77, 3519-3523.
Goslin,K. and Banker,G.A. (1989) J. Cell Biol., 108, 1507-1516.
Gratzl,M. and Langley,K. (eds) (1990) Markers for Neural and Endocrine
Cells. VCH-Verlagsgesellschaft, Weinheim, FRG, in press.
Halban,P.A., Powers,S.L., George,K.L. and Bonner-Weir,S. (1988)
Endocrinology, 123, 113-119.
Hell,J.W., Maycox,P.R., Stadler,H. and Jahn,R. (1988) EMBO J., 7,
3023 -3029.
Hokfelt,T., Johansson,O. and Goldstein,M. (1984) Science, 225,
1326-1334.
Jahn,R., Schiebler,W., Ouimet,C. and Greengard,P. (1985) Proc. Natl
Acad. Sci. USA, 82, 4137-4141.
Johnston,P.A., Cameron,P.L., Stukenbrok,H., Jahn,R., De Camilli,P. and
Sudhof,T.C. (1989) EMBO J., 8, 2863-2872.
Julien,J.-F., Samama,P. and Mallet,J. (1990) J. Neurochem., 54, 703 -705.
Katarova,Z., Szabo,G., Mugnaini,E. and Greenspan,R.J. (1989) Eur. J.
Neurosci., 2, 190-202.
Kobayashi,Y., Kaufman,D.L. and Tobin,A.J. (1987) J. Neurosci., 7,
2768-2772.
Laemmli,U.K. (1970) Nature, 227, 680-685.
Le Douarin,N.N. (1990) Cell, 53, 169-171.
Legay,F., Henry,S. and Tappaz,M. (1987) J. Neurochem., 48, 1022- 1026.
McLaughlin,B.J., Wood,J.G., Saito,K., Roberts,E. and Wu,J.Y. (1975)
Brain Res., 85, 355-371.
Matthew,W.D., Tsavaler,L. and Reichardt,L.F. (1981) J. Cell Biol., 91,
257-269.
Mignery,G.A., Sudhof,T.C., Takei,K. and De Camilli,P. (1989) Nature,
342, 192-195.
Mugnaini,E. and Oertel,W.H. (1985) In Bjorklund,A. and Hokfelt,T. (eds),
Handbook of Chemical Neuroanatomy. Elsevier, Amsterdam, Vol. 4,
pp. 436-608.
Nagai,T., McGeer,P.L., Araki,M. and McGeer,E.G. (1984) In
Bjorklund,A., Hokfelt,T. and Kuhar,M.J. (eds), Handbook of Chemical
Neuroanatomy. Elsevier, Amsterdam, Vol. 3, pp. 247-272.
Navone,F., Jahn,R., Di Gioia,G., Stukenbrok,H., Greengard,P. and De
Camilli,P. (1986) J. Cell Biol., 193, 2511-2527.
Navone,F., Di Gioia,G., Jahn,R., Browning,M., Greengard,P. and De
Camilli,P. (1989) J. Cell Biol., 109, 3425-3433.
Oertel,W.H., Schmechel,D.E., Tappaz,M.L. and Kopin,I.J. (1981a)
Neuroscience, 6, 2689-2700.
Oertel,W.H., Schmechel,D.E., Mugnaini,E., Tappaz,M.L. and Kopin,I.J.
(1981b) Neuroscience, 6, 2715-2735.
Okada,Y. (1986) In Erdo,S.L. and Bowery,N.G. (eds), GABAergic
Mechanisms in the Mammalian Periphery. Raven Press, New York,
pp. 223-240.
Okada,Y., Taniguchi,H. and Shimada,C. (1976) Science, 194, 620-622.
Passariello,N., Giugliano,D., Torella,R., Sgambato,S., Coppola,L. and
Frascolla,N. (1982) J. Clin. Endocrinol. Metab., 54, 1145-1149.
Pearse,A.G.E. (1977) Med. Biol., 55, 115-125.
Polak,J.M., Bloom,S.R. and Marangos,P.J. (1984) In Falkmer,S.,
Hakanson,R. and Sundler,F. (eds), Evolution and Tumor Pathology of
the Neuroendocrine System. Elsevier, Amsterdam, pp. 433-542.
Powers,A.C., Efrat,S., Mojsov,S., Spector,D., Habener,J.F. and
Hanahan,D. (1990) Diabetes, 39, 406-414.
Reetz,A.T., Solimena,M., Folli,F., Takei,K. and De Camilli,P. (1990a)
Cell Biol. Int. Rep., 14 (suppl.), 52.
Reetz,A.T., Solimena,M., Matteoli,M., Takei,K., Folli,F. and De
Camilli,P. (1990b) J. Cell Biol., 111, 312a.
Robbins,M.S., Grouse,L.H., Sorenson,R.L. and Elde,R.P. (1981) Diabetes,
30, 168-171.
Rorsman,P., Berggren,P.-O., Bokvist,K., Ericson,H., Mohler,H.,
Ostenson,C.-G. and Smith,P.A. (1989) Nature, 341, 233-236.
Rosa,P., Fumagalli,G., Zanini,A. and Huttner,W.B. (1985a) J. Cell Biol.,
100, 928-937.
Rosa,?., Hille,A., Lee,R.W.H., Zanini,A., De Camilli,P. and Huttner,W.
(1985b) J. Cell Biol., 101, 1999-2011.
Saito,K., Barber,R., Wu,J.-Y., Matsuda,T., Roberts,E. and Vaughn,J.E.
(1974) Proc. Natl Acad. Sci. USA, 71, 269-273.
Schwartz,E.A. (1987) Science, 238, 350-355.
Schwartzman,M.J., Mitsumoto,H., Estes,M.L., Chou,S.M., LaFranchise,
E.F., De Camilli,P. and Solimena,M. (1991) J. Neurol., in press.
Schweitzer,E.S. and Paddock,S. (1990) J. Cell Sci., 96, 375-381.
Slot,J.W., Geuze,H.J. (1983) In Cuello,A.C., (ed.), IBRO Handbook Series:
Methods in Neuroscience. Vol. 3. Immunocytochemistry. John Wiley &
Sons, New York, pp. 323-372.
Solimena,M., Folli,F., Aparisi,R., Pozza,G. and De Camilli,P. (1990) New
Engl. J. Med., 322, 1555- 1560.
Storm-Mathisen,J., Leknes,A.K., Bore,A.T., Vaaland,J.L., Edminson,P.,
Haug,F.M.S. and Ottersen,O.P. (1983) Nature, 301, 517-520.
Taniguchi,H., Yoshioka,M., Tsutou,E., Ejiri,K., Tamagawa,M.,
Murakami,K., Utsumi,M., Shigeaki,B. and Okada,Y. (1980) Biomed.
Res., 1 (suppl.), 180-182.
Teitelman,G. and Lee,J.K. (1987) Dev. Biol., 121, 454-466.
Teitelman,G., Lee,J.K. and Alpert,S. (1987) Cell Tissue Res., 250,
435-439.
Tooze,J. and Burke,B. (1987) J. Cell Biol., 104, 1047-1057.
Tooze,J., Hollinshead,M., Fuller,S.D., Tooze,S.A. and Huttner,W.B.
(1989) Eur. J. Cell Biol., 49, 259-273.
Towbin,H.T., Staehelin,T., Gordon,J. (1979) Proc. Natl. Acad. Sci., 76,
4350-4354.
Vincent,S.R., Hockfelt,T., Wu,J.-Y., Elde,R.P., Morgan,L.M. and
Kimmel,J.R. (1983) Neuroendocrinology, 36, 197-204.
Wenthold,R., Zempel,J.M., Parakkal,M.H., Reeks,K.A. and Altschuler,
R.A. (1986) Brain Res., 380, 7-18.
Wiedenmann,B. and Franke,W.W. (1985) Cell, 41, 1017-1028.
Wiedenmann,B., Rehm,H., Knierim,M. and Becker,C.M. (1988) FEBS
Lett., 240, 71-77.
Williams,R.H. and Porte,D. (1974) In Williams,R.H. (ed.), Textbook of
Endocrinology. W.B.Saunders Co., Philadelphia, PA, pp. 502-626.
Wu,J.W. (1983) In Cuello,A.C. (ed.) IBRO Handbook Series: Methods
in Neuroscience. Vol. 3. Immunocytochemistry. John Wiley and Sons,
New York. pp. 159-191.
Wyborski,R.J., Bond,R.W. and Gottlieb,D.I. (1990) Mol. Brain Res., 8,
193-198.
Yuan,L., Barriocanal,J.G., Bonifacino,J.S. and Sandoval,I.V. (1987) J. Cell
Biol., 105, 215-227.
Received on January 2, 1991
1284
